Skip to main content
Erschienen in: Intensive Care Medicine 12/2013

01.12.2013 | Original Article

Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis

verfasst von: D. Cook, Y. Arabi, N. D. Ferguson, D. Heels-Ansdell, A. Freitag, E. McDonald, F. Clarke, S. Keenan, G. Pagliarello, W. Plaxton, M. Herridge, T. Karachi, S. Vallance, J. Cade, T. Crozier, S. Alves da Silva, R. Costa Filho, N. Brandao, I. Watpool, T. McArdle, G. Hollinger, Y. Mandourah, M. Al-Hazmi, N. Zytaruk, N. K. J. Adhikari, The PROTECT Research Coordinators, PROTECT Investigators, Canadian Critical Care Trials Group and the, Australian and New Zealand Intensive Care Society Clinical Trials Group

Erschienen in: Intensive Care Medicine | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To analyze the frequency, rationale and determinants of attending physicians requesting that their eligible patients not be approached for participation in a thromboprophylaxis trial.

Methods

Research personnel in 67 centers prospectively documented eligible non-randomized patients due to physicians declining to allow their patients to be approached.

Results

In 67 centers, 3,764 patients were enrolled, but 1,460 eligible patients had no consent encounter. For 218 (14.9 %) of these, attending physicians requested that their patients not be approached. The most common reasons included a high risk of bleeding (31.2 %) related to fear of heparin bioaccumulation in renal failure, the presence of an epidural catheter, peri-operative status or other factors; specific preferences for thromboprophylaxis (12.4 %); morbid obesity (9.6 %); uncertain prognosis (6.4 %); general discomfort with research (3.7 %) and unclear reasons (17.0 %). Physicians were more likely to decline when approached by less experienced research personnel; considering those with >10 years of experience as the reference category, the odds ratios (OR) for physician refusals to personnel without trial experience was 10.47 [95 % confidence interval (CI) 2.19–50.02] and those with less than 10 years experience was 1.72 (95 % CI 0.61–4.84). Physicians in open rather than closed units were more likely to decline (OR 4.26; 95 % CI 1.27–14.34). Refusals decreased each year of enrollment compared to the pilot phase.

Conclusions

Tracking, analyzing, interpreting and reporting the rates and reasons for physicians declining to allow their patients to be approached for enrollment provides insights into clinicians’ concerns and attitudes to trials. This information can encourage physician communication and education, and potentially enhance efficient recruitment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Taylor KM, Margolese RG, Soskolne CL (1984) Physicians’ reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 310:1363–1367PubMedCrossRef Taylor KM, Margolese RG, Soskolne CL (1984) Physicians’ reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 310:1363–1367PubMedCrossRef
2.
Zurück zum Zitat Ellis PM, Butow PN, Simes RJ et al (1999) Barriers to participation in randomised clinical trials for early breast cancer among Australian cancer specialists. Aust N Z J Surg 69:505–510CrossRef Ellis PM, Butow PN, Simes RJ et al (1999) Barriers to participation in randomised clinical trials for early breast cancer among Australian cancer specialists. Aust N Z J Surg 69:505–510CrossRef
3.
Zurück zum Zitat Rahman M, Morita S, Fukui T, Sakamoto J (2004) Physicians’ reasons for not entering their patients in a randomized controlled trial in Japan. Tohoku J Exp Med 203:104–109CrossRef Rahman M, Morita S, Fukui T, Sakamoto J (2004) Physicians’ reasons for not entering their patients in a randomized controlled trial in Japan. Tohoku J Exp Med 203:104–109CrossRef
4.
Zurück zum Zitat Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, Troché G, Ricard JD, Nitenberg G, Papazian L, Azoulay E, Bellissant E, The CATS Study Group (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676–684PubMedCrossRef Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, Troché G, Ricard JD, Nitenberg G, Papazian L, Azoulay E, Bellissant E, The CATS Study Group (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676–684PubMedCrossRef
5.
Zurück zum Zitat De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, SOAPII Investigators (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362(9):779–789. doi:10.1056/NEJMoa0907118 PubMedCrossRef De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, SOAPII Investigators (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362(9):779–789. doi:10.​1056/​NEJMoa0907118 PubMedCrossRef
6.
Zurück zum Zitat Clarke F, Zytaruk N, Fowler R, Heels-Ansdell D, Crowther M, Freitag A, Karachi T, Pagliarello G, Cade J, Bellomo R, Keenan S, Reynolds S, Wood G, Paunovic B, Plaxton W, Hollinger G, Chittock D, Poirier G, Lopes R, Mandourah Y, Shaikh N, Al-Hazmi M, Al-Azem A, Ostermann M, Brandao N, Costa Filho R, Alves da Silva S, Teixeira C, Rocha M, Guimaraes H, Cook D (2012) Physicians declining patient enrolment into clinical trials: incidence and insights. Am J Resp Crit Care Med 185:A2543 (abstract) Clarke F, Zytaruk N, Fowler R, Heels-Ansdell D, Crowther M, Freitag A, Karachi T, Pagliarello G, Cade J, Bellomo R, Keenan S, Reynolds S, Wood G, Paunovic B, Plaxton W, Hollinger G, Chittock D, Poirier G, Lopes R, Mandourah Y, Shaikh N, Al-Hazmi M, Al-Azem A, Ostermann M, Brandao N, Costa Filho R, Alves da Silva S, Teixeira C, Rocha M, Guimaraes H, Cook D (2012) Physicians declining patient enrolment into clinical trials: incidence and insights. Am J Resp Crit Care Med 185:A2543 (abstract)
7.
Zurück zum Zitat Cook D, Meade M, Guyatt G et al (2011) PROphylaxis for ThromboEmbolism in Critical care Trial protocol and analysis plan. J Crit Care 26:223.e1–223.e9CrossRef Cook D, Meade M, Guyatt G et al (2011) PROphylaxis for ThromboEmbolism in Critical care Trial protocol and analysis plan. J Crit Care 26:223.e1–223.e9CrossRef
8.
Zurück zum Zitat PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314CrossRef PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314CrossRef
9.
Zurück zum Zitat Cook DJ, Rocker G, Meade M et al (2005) PROphylaxis for ThromboEmbolism in Critical care Trial (PROTECT): a pilot study. J Crit Care 20:364–372PubMedCrossRef Cook DJ, Rocker G, Meade M et al (2005) PROphylaxis for ThromboEmbolism in Critical care Trial (PROTECT): a pilot study. J Crit Care 20:364–372PubMedCrossRef
10.
Zurück zum Zitat Douketis J, Cook DJ, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hebert PC, Pagliarello G, Marshall JC, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther MA, Canadian Critical Care Trials Group (2008) Renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and pharmacodynamics. The DIRECT (Dalteparin’s Influence on REnally Compromised anti-Ten-A) Study. Arch Intern Med 168(16):1805–1812PubMedCrossRef Douketis J, Cook DJ, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hebert PC, Pagliarello G, Marshall JC, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther MA, Canadian Critical Care Trials Group (2008) Renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and pharmacodynamics. The DIRECT (Dalteparin’s Influence on REnally Compromised anti-Ten-A) Study. Arch Intern Med 168(16):1805–1812PubMedCrossRef
11.
Zurück zum Zitat Austin PC, Goel V, Van Walraven C (2001) An introduction to multilevel regression models. Can J Public Health 92(2):150PubMed Austin PC, Goel V, Van Walraven C (2001) An introduction to multilevel regression models. Can J Public Health 92(2):150PubMed
12.
Zurück zum Zitat Mehta S, Burry LD, Cook DJ, Fergusson DA, Steinberg M, Granton JT, Herridge MS, Ferguson ND, Devlin JW, Tanios MA, Dodek PE, Fowler RA, Burns KE, Jacka MJ, Olafson K, Skrobik Y, Hebert PC, Sabri H, Meade MO, SLEAP Investigators and the Canadian Critical Care Trials Group (2012) A randomized trial of daily sedative interruption in mechanically ventilated critically ill patients cared for with a sedation protocol. JAMA. doi:10.1001/jama.2012.1387 Mehta S, Burry LD, Cook DJ, Fergusson DA, Steinberg M, Granton JT, Herridge MS, Ferguson ND, Devlin JW, Tanios MA, Dodek PE, Fowler RA, Burns KE, Jacka MJ, Olafson K, Skrobik Y, Hebert PC, Sabri H, Meade MO, SLEAP Investigators and the Canadian Critical Care Trials Group (2012) A randomized trial of daily sedative interruption in mechanically ventilated critically ill patients cared for with a sedation protocol. JAMA. doi:10.​1001/​jama.​2012.​1387
13.
Zurück zum Zitat Ferguson ND, Cook DJ, Guyatt GH, Mehta S, Hand L, Austin P, Zhou Q, Matte A, Walter S, Lamontagne F, Granton JT, Arabi Y, Arroliga A, Stewart TE, Slutsky AS, Meade MO (2013) OSCILLATE Trial Investigators and the Canadian Critical Care Trials Group. N Engl J Med 368(9):798–805CrossRef Ferguson ND, Cook DJ, Guyatt GH, Mehta S, Hand L, Austin P, Zhou Q, Matte A, Walter S, Lamontagne F, Granton JT, Arabi Y, Arroliga A, Stewart TE, Slutsky AS, Meade MO (2013) OSCILLATE Trial Investigators and the Canadian Critical Care Trials Group. N Engl J Med 368(9):798–805CrossRef
14.
Zurück zum Zitat The RENAL Replacement Therapy Trial Investigators (2009) Screening and study enrolment in the randomized evaluation of normal vs. augmented level (RENAL) replacement therapy trial. Blood Purif 27:199–205CrossRef The RENAL Replacement Therapy Trial Investigators (2009) Screening and study enrolment in the randomized evaluation of normal vs. augmented level (RENAL) replacement therapy trial. Blood Purif 27:199–205CrossRef
15.
Zurück zum Zitat Cook DJ, McMullin J, Hodder R, Heule M, Pinilla J, Dodek P, Stewart T, Canadian ICU Directors Group (2001) Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey. Crit Care 5(6):336–342PubMedCrossRef Cook DJ, McMullin J, Hodder R, Heule M, Pinilla J, Dodek P, Stewart T, Canadian ICU Directors Group (2001) Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey. Crit Care 5(6):336–342PubMedCrossRef
16.
Zurück zum Zitat Cooper DJ, Bishop N, Cade J, Finfer S, Gallus A, Myburgh J, Australian and New Zealand Intensive Care Society Clinical Trials Group (2005) Thromboprophylaxis for intensive care patients in Australia and New Zealand: a brief survey report. J Crit Care 20(4):354–356PubMedCrossRef Cooper DJ, Bishop N, Cade J, Finfer S, Gallus A, Myburgh J, Australian and New Zealand Intensive Care Society Clinical Trials Group (2005) Thromboprophylaxis for intensive care patients in Australia and New Zealand: a brief survey report. J Crit Care 20(4):354–356PubMedCrossRef
17.
Zurück zum Zitat Cook DJ, Meade MO, Guyatt GH, Griffith LE, Granton J, Geerts W, Crowther M, Canadian Critical Care Trials Group (2004) Clinically important deep vein thrombosis in the ICU: a survey of intensivists. Crit Care 8:R145–R152PubMedCrossRef Cook DJ, Meade MO, Guyatt GH, Griffith LE, Granton J, Geerts W, Crowther M, Canadian Critical Care Trials Group (2004) Clinically important deep vein thrombosis in the ICU: a survey of intensivists. Crit Care 8:R145–R152PubMedCrossRef
18.
Zurück zum Zitat Lacherade JC, Cook DJ, Heyland D, Chrusch C, Brochard L, Brun-Buisson C, French and Canadian ICU Directors Groups (2003) Prevention of venous thromboembolism (VTE) in critically ill medical patients: a Franco-Canadian cross-sectional study. J Crit Care 18(4):228–237PubMedCrossRef Lacherade JC, Cook DJ, Heyland D, Chrusch C, Brochard L, Brun-Buisson C, French and Canadian ICU Directors Groups (2003) Prevention of venous thromboembolism (VTE) in critically ill medical patients: a Franco-Canadian cross-sectional study. J Crit Care 18(4):228–237PubMedCrossRef
19.
Zurück zum Zitat Cook DJ, Laporta D, Skrobik Y, Peters S, Sharpe M, Murphy P, Chin D, Crowther M, Canadian ICU Directors Group (2001) Prevention of venous thromboembolism in critically ill surgery patients: a cross-sectional study. J Crit Care 16(4):161–166PubMedCrossRef Cook DJ, Laporta D, Skrobik Y, Peters S, Sharpe M, Murphy P, Chin D, Crowther M, Canadian ICU Directors Group (2001) Prevention of venous thromboembolism in critically ill surgery patients: a cross-sectional study. J Crit Care 16(4):161–166PubMedCrossRef
20.
Zurück zum Zitat Patel R, Cook DJ, Meade MO, Griffith L, Mehta S, Rocker G, Marshall J, Hodder R, Martin C, Heyland D, Peters S, Muscedere J, Soth M, Campbell N, Guyatt GH, Canadian Critical Care Trials Group (2005) Burden of illness: thrombo-embolism in critical care (BITEC) study. J Crit Care 20:341–347PubMedCrossRef Patel R, Cook DJ, Meade MO, Griffith L, Mehta S, Rocker G, Marshall J, Hodder R, Martin C, Heyland D, Peters S, Muscedere J, Soth M, Campbell N, Guyatt GH, Canadian Critical Care Trials Group (2005) Burden of illness: thrombo-embolism in critical care (BITEC) study. J Crit Care 20:341–347PubMedCrossRef
21.
Zurück zum Zitat Cook DJ, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt GH (2005) Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence and risk factors. Crit Care Med 33(7):1565–1571PubMedCrossRef Cook DJ, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt GH (2005) Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence and risk factors. Crit Care Med 33(7):1565–1571PubMedCrossRef
22.
Zurück zum Zitat Cook DJ, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, Skrobik Y, Albert M, Fowler R, Hebert P, Pagliarello G, Friedrich J, Freitag A, Karachi T, Rabbat C, Heels-Ansdell D, Geerts W, Crowther M, Canadian Critical Care Trials Group (2008) Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency: prevalence, incidence and risk factors. Crit Care 12(2):R32-1–R32-9CrossRef Cook DJ, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, Skrobik Y, Albert M, Fowler R, Hebert P, Pagliarello G, Friedrich J, Freitag A, Karachi T, Rabbat C, Heels-Ansdell D, Geerts W, Crowther M, Canadian Critical Care Trials Group (2008) Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency: prevalence, incidence and risk factors. Crit Care 12(2):R32-1–R32-9CrossRef
23.
Zurück zum Zitat Lauzier F, Arnold D, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates J, Karachi T, Lopes R, Zytaruk N, Finfer S, Crowther M, Cook D For the PROTECT Investigators, the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2013) Risk factors and consequences of major bleeding in medical-surgical critically Ill patients: a cohort study. Intensive Care Med (in press). Lauzier F, Arnold D, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates J, Karachi T, Lopes R, Zytaruk N, Finfer S, Crowther M, Cook D For the PROTECT Investigators, the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2013) Risk factors and consequences of major bleeding in medical-surgical critically Ill patients: a cohort study. Intensive Care Med (in press).
24.
Zurück zum Zitat Zarychanski R, Lim W, Rocha M, McIntyre L, Lamontagne F, Dodek P, Pai M, Cooper DJ, Alhashemi J, Zytaruk N (2011) Do statins influence DVT risk in critically ill patients? Crit Care Med 39(12 :suppl):A112 Zarychanski R, Lim W, Rocha M, McIntyre L, Lamontagne F, Dodek P, Pai M, Cooper DJ, Alhashemi J, Zytaruk N (2011) Do statins influence DVT risk in critically ill patients? Crit Care Med 39(12 :suppl):A112
25.
Zurück zum Zitat Zytaruk N, Meade M, Mehta S, Hall R, Granton J, Ferguson ND, Freitag A, Muscedere J, Fowler R, Skrobik Y, Jacka M, Marshall J, Lauzier F, Lamontagne F, Turgeon A, Vlahakis N, Klinger J, Devereaux PJ, Ostermann M, Berwanger O, Khwaja K, Burry L, Freidrich J, Burns KEA, Herridge M, Cooper DJ, Bersten A, Heels-Ansdell D, Cook DJ, PROTECT Investigators, the CCCTG and the ANZICS-CTG (2012) Risk factors for pulmonary embolism in medical-surgical ICU patients. Am J Resp Crit Care Med 185:A2359 Zytaruk N, Meade M, Mehta S, Hall R, Granton J, Ferguson ND, Freitag A, Muscedere J, Fowler R, Skrobik Y, Jacka M, Marshall J, Lauzier F, Lamontagne F, Turgeon A, Vlahakis N, Klinger J, Devereaux PJ, Ostermann M, Berwanger O, Khwaja K, Burry L, Freidrich J, Burns KEA, Herridge M, Cooper DJ, Bersten A, Heels-Ansdell D, Cook DJ, PROTECT Investigators, the CCCTG and the ANZICS-CTG (2012) Risk factors for pulmonary embolism in medical-surgical ICU patients. Am J Resp Crit Care Med 185:A2359
26.
Zurück zum Zitat Zarychanski R, Lauzier F, Turgeon A, Marshall J, Nates J, Cox M, Arabi Y, Qushmaq I, Zytaruk N, Cook DJ (2011) VTE risk factors in medical-surgical ICU patients. Crit Care Med 39(12 suppl):A672 Zarychanski R, Lauzier F, Turgeon A, Marshall J, Nates J, Cox M, Arabi Y, Qushmaq I, Zytaruk N, Cook DJ (2011) VTE risk factors in medical-surgical ICU patients. Crit Care Med 39(12 suppl):A672
27.
Zurück zum Zitat Segelov E, Tattersall MHN, Coates AS (1992) Redressing the balance: ethics of not entering an eligible patient on a randomized clinical trial. Ann Oncol 3:103–105PubMedCrossRef Segelov E, Tattersall MHN, Coates AS (1992) Redressing the balance: ethics of not entering an eligible patient on a randomized clinical trial. Ann Oncol 3:103–105PubMedCrossRef
28.
Zurück zum Zitat Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD (2005) Systematic review to determine whether participation in a trial influences outcome. BMJ 330:1175–1182PubMedCrossRef Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD (2005) Systematic review to determine whether participation in a trial influences outcome. BMJ 330:1175–1182PubMedCrossRef
29.
Zurück zum Zitat Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescot R (1999) Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 52(12):1143–1156PubMedCrossRef Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescot R (1999) Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 52(12):1143–1156PubMedCrossRef
30.
Zurück zum Zitat Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K (2009) A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ 180(10):E47–E57PubMedCrossRef Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K (2009) A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ 180(10):E47–E57PubMedCrossRef
Metadaten
Titel
Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis
verfasst von
D. Cook
Y. Arabi
N. D. Ferguson
D. Heels-Ansdell
A. Freitag
E. McDonald
F. Clarke
S. Keenan
G. Pagliarello
W. Plaxton
M. Herridge
T. Karachi
S. Vallance
J. Cade
T. Crozier
S. Alves da Silva
R. Costa Filho
N. Brandao
I. Watpool
T. McArdle
G. Hollinger
Y. Mandourah
M. Al-Hazmi
N. Zytaruk
N. K. J. Adhikari
The PROTECT Research Coordinators
PROTECT Investigators
Canadian Critical Care Trials Group and the
Australian and New Zealand Intensive Care Society Clinical Trials Group
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 12/2013
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-013-3074-x

Weitere Artikel der Ausgabe 12/2013

Intensive Care Medicine 12/2013 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.